June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
(+)-Pentazocine ((+)-PTZ), a high affinity sigma 1 receptor (σ1R) ligand preserves cone function in the Pde6rd10 (Rd10) mouse model of retinitis pigmentosa
Author Affiliations & Notes
  • Jing Wang
    Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, GA
    James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, GA
  • Alan Saul
    James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, GA
    Ophthalmology, Georgia Regents University, Augusta, GA
  • Vadivel Ganapathy
    James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, GA
  • Sylvia B Smith
    Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, GA
    James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, GA
  • Footnotes
    Commercial Relationships Jing Wang, None; Alan Saul, None; Vadivel Ganapathy, None; Sylvia Smith, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5475. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jing Wang, Alan Saul, Vadivel Ganapathy, Sylvia B Smith; (+)-Pentazocine ((+)-PTZ), a high affinity sigma 1 receptor (σ1R) ligand preserves cone function in the Pde6rd10 (Rd10) mouse model of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5475.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: σ1R, a unique transmembrane protein located at the ER, mitochondria, nuclear and plasma membranes, has retinal neuroprotective properties in vitro (primary RGCs, Mueller et al, 2014; Dun et al 2007) and in vivo (Ins2Akita/+ diabetic mouse, Smith et al, 2008). We asked whether (+)-PTZ, a high-affinity σ1R ligand, could attenuate rod-cone degeneration in Pde6rd10 mice, which demonstrate rapid, profound photoreceptor (PRC) loss.

Methods: Pde6rd10 mice were injected i.p with (+)-PTZ (0.5 mg · kg−1) every other day beginning at P14. Mice were subjected to ERG and OCT at P35. At P42, eyes were enucleated, cryosectioned & subjected to TUNEL assay to evaluate apoptosis; morphometric analysis to assess PRC loss and immunohistochemistry (IMH) to examine rods (anti-rhodopsin), cones (anti-cone-arrestin), rod bipolar cells (anti-PKCα) and Müller cell activation (anti-GFAP). One-way ANOVA was used to compare Pde6rd10 data to that of age-matched wild type (WT) and non-injected-Pde6rd10 mice.

Results: ERG showed partial rescue of scotopic (rod) responses in (+)-PTZ-injected versus non-injected-Pde6rd10 mice and significant rescue of photopic (cone) responses, especially b-wave amplitude (~50% of WT mice - compared to virtually no response in non-injected-Pde6rd10 mice). Remarkably, ERG using low temporal frequencies (natural noise), mediated almost entirely by cones, showed similar strength responses in (+)-PTZ-injected mice versus WT. OCT revealed greater retinal thickness in (+)-PTZ-injected versus non-injected Pde6rd10 mice, which was confirmed by morphometric analysis: WT: 203.03±36.22 µm; Pde6rd10: 84.02±35.65 µm; (+)-PTZ-injected-Pde6rd10: 115.99±28.59 mm. The number of PRC rows was significantly greater in (+)-PTZ-injected (2.3±1.1) versus non-injected Pde6rd10 mice (0.96±0.6). The number of TUNEL positive PRCs per retina section was markedly reduced in (+)-PTZ-injected (5.3±2.0) versus non-injected Pde6rd10 mice (32.8±15.6). IMH showed preservation of cones and bipolar cells and decreased Müller cell GFAP levels in (+)-PTZ-injected versus non-injected-Pde6rd10 mice.

Conclusions: This is the first in vivo attempt targeting σ1R for treatment of severe retinopathy. (+)-PTZ administration preserved cone function in Pde6rd10 mice suggesting that σ1R activation may offer a novel, highly promising therapeutic strategy for severe retinal degenerations.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×